Drug Profile


Alternative Names: 9-THC; Delta9-Tetrahydrocannabinol; Deltanyne; Dronabinol inhaled; Elevat; Marinol; NSC-134454; Pulmonary dronabinol - Solvay/Nektar Therapeutics; δ9-tetrahydrobannabinol

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Unimed Pharmaceuticals
  • Developer Nektar Therapeutics; Unimed Pharmaceuticals
  • Class Antiemetics; Appetite stimulants; Cannabinoids; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Anorexia nervosa; Nausea and vomiting
  • Discontinued Migraine

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Oct 2005 Phase-II clinical trials in Migraine (Inhalation)
  • 20 May 2005 Data from a media release have been added to the Advances in the Treatment of Nausea and Migraine therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top